Indication: Acute respiratory viral infections and influenza. Primary dysmenorrhea. Dysfunctional menorrhagia. Inflammatory diseases of the musculoskeletal system: rheumatoid arthritis, rheumatism, ankylosing spondylitis. Low and medium intensity pain syndrome: muscle, joint, traumatic, toothache, headache of various etiologies, postoperative and postpartum pain.
active substance: mefenamic acid;
1 capsule contains mefenamic acid 500 mg;
excipients: talc, stearic acid, corn starch, sodium lauryl sulfate, crospovidone.
Mefenaminca is a non-steroidal anti-inflammatory drug (NSAID). Has anti-inflammatory, analgesic and antipyretic effects. Inhibits the synthesis of inflammatory mediators (prostaglandins, serotonin, kinins), reduces the activity of proteases of lysosomes involved in the inflammatory response. Affects the phases of exudation and proliferation. Stabilizes protein ultrastructures and cell membranes, reduces vascular permeability and tissue edema. Inhibits cell proliferation in the inflammatory focus; increases cell resistance and stimulates wound healing. The antipyretic effect is due to the inhibition of prostaglandin synthesis and the effect on the thermoregulatory center. Stimulates the formation of interferon.
- Acute respiratory viral infections and influenza.
- Primary dysmenorrhea. Dysfunctional menorrhagia.
- Inflammatory diseases of the musculoskeletal system: rheumatoid arthritis, rheumatism, ankylosing spondylitis.
- Low and medium intensity pain syndrome: muscle, joint, traumatic, toothache, headache of various etiologies, postoperative and postpartum pain.
Hypersensitivity to the components of the drug. History of bronchospasm, Quincke’s edema, rhinitis, bronchial asthma, or urticaria after acetylsalicylic acid or other NSAIDs. Concomitant use of specific COX-2 inhibitors. Gastric and duodenal ulcers present or in history, inflammatory bowel disease, hematopoietic diseases, severe heart failure, severe hepatic or renal impairment, gastrointestinal bleeding or perforation caused by non-steroidal anti-inflammatory drugs, treatment of pain after surgery.
Recommended for children over 12 years old.
Use during pregnancy or breastfeeding
The drug should not be used by women during pregnancy and breastfeeding.
Method of application and dosage
Apply Mefenaminca orally, take the drug after meals.
Adults and children over 12 years of age should be prescribed 250-500 mg 3-4 times a day. If necessary, the daily dose can be increased to 3 g per day. After achieving a therapeutic effect, the daily dose should be reduced to 1 g
The course of treatment for diseases of the joints can last from 20 days to 2 months or more. In the treatment of pain, the course of treatment lasts up to 7 days.
Symptoms: epigastric pain, nausea, vomiting, drowsiness, headache, rarely – diarrhea, disorientation, agitation, tinnitus, loss of consciousness, sometimes convulsions (mefenamic acid tends to induce tonic-clonic seizures in overdose). In severe cases – gastrointestinal bleeding, respiratory depression, hypertension, twitching of certain muscle groups, coma. In cases of significant poisoning, renal and hepatic failure are possible.
Treatment: no specific antidote. Gastric lavage with a suspension of activated charcoal. Urinary alkalinization, forced diuresis. Symptomatic therapy. Hemosorption and hemodialysis are ineffective due to the strong binding of mefenamic acid to blood proteins. Renal and liver function should be closely monitored. Frequent or prolonged seizures should be treated with intravenous diazepam.
Drug therapy may be accompanied by:
- stomach pain;
- violation of the heart rhythm;
- increased pressure;
- the discovery of bleeding in the gastrointestinal tract;
- bronchial spasms;
- impaired renal function;
- changes in blood counts;
- skin rashes;
- anaphylactic shock.
The medicine must be stored at a temperature of no more than 25 degrees.